Introduction |
|
vii | |
|
1 Choosing Among Antibiotics Within a Class: Beta-Iactams, Macrolides, Aminoglycosides, and Fluoroquinolones |
|
|
1 | (6) |
|
2 Choosing Among Antifungal Agents: Polyenes, Azoles, and Echinocandins |
|
|
7 | (8) |
|
3 How Antibiotic Dosages Are Determined Using Susceptibility Data, Pharmacodynamics, and Treatment Outcomes |
|
|
15 | (2) |
|
4 Community-Associated Methicillin-Resistant Staphylococcus aureus |
|
|
17 | (4) |
|
5 Antimicrobial Therapy for Newborns |
|
|
21 | (24) |
|
A Recommended Therapy for Selected Newborn Conditions |
|
|
22 | (17) |
|
B Antimicrobial Dosages for Neonates |
|
|
39 | (4) |
|
|
43 | (1) |
|
|
43 | (1) |
|
E Use of Antimicrobials During Pregnancy or Breastfeeding |
|
|
44 | (1) |
|
6 Antimicrobial Therapy According to Clinical Syndromes |
|
|
45 | (60) |
|
A Skin and Soft Tissue Infections |
|
|
47 | (5) |
|
|
52 | (2) |
|
|
54 | (3) |
|
D Ear and Sinus Infections |
|
|
57 | (4) |
|
E Oropharyngeal Infections |
|
|
61 | (3) |
|
F Lower Respiratory Tract Infections |
|
|
64 | (11) |
|
G Cardiovascular Infections |
|
|
75 | (6) |
|
H Gastrointestinal Infections |
|
|
81 | (6) |
|
I Genital and Sexually Transmitted Infections |
|
|
87 | (4) |
|
J Central Nervous System Infections |
|
|
91 | (4) |
|
K Urinary Tract Infections |
|
|
95 | (2) |
|
L Miscellaneous Systemic Infections |
|
|
97 | (8) |
|
7 Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens |
|
|
105 | (24) |
|
A Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Gram Positive) |
|
|
106 | (2) |
|
B Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Gram Negative) |
|
|
108 | (2) |
|
C Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Anaerobes) |
|
|
110 | (2) |
|
D Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens |
|
|
112 | (17) |
|
8 Preferred Therapy for Specific Fungal Pathogens |
|
|
129 | (14) |
|
A Overview of Fungal Pathogens and Usual Pattern of Susceptibility to Antifungals |
|
|
130 | (2) |
|
|
132 | (10) |
|
C Localized Mucocutaneous Infections |
|
|
142 | (1) |
|
9 Preferred Therapy for Specific Viral Pathogens |
|
|
143 | (16) |
|
A Overview of Non-HIV Viral Pathogens and Usual Pattern of Susceptibility to Antivirals |
|
|
144 | (2) |
|
B Preferred Therapy for Specific Viral Pathogens |
|
|
146 | (13) |
|
10 Preferred Therapy for Specific Parasitic Pathogens |
|
|
159 | (18) |
|
11 Alphabetic Listing of Antimicrobials |
|
|
177 | (28) |
|
A Systemic Antimicrobials With Dosage Forms and Usual Dosages |
|
|
179 | (18) |
|
B Topical Antimicrobials (Skin, Eye, Ear) |
|
|
197 | (8) |
|
12 Antibiotic Therapy for Children Who Are Obese |
|
|
205 | (4) |
|
13 Sequential Parenteral-Oral Antibiotic Therapy (Oral Step-down Therapy) for Serious Infections |
|
|
209 | (2) |
|
14 Antimicrobial Prophylaxis/Prevention of Symptomatic Infection |
|
|
211 | (14) |
|
A Postexposure Short-term Antimicrobial Prophylaxis |
|
|
213 | (7) |
|
B Long-term Antimicrobial Prophylaxis to Prevent Symptomatic Disease |
|
|
220 | (1) |
|
C Preemptive Treatment/Latent Infection Treatment ("Prophylaxis of Symptomatic Disease in Children Who Have Asymptomatic Infection") |
|
|
221 | (1) |
|
D Surgical/Procedure Prophylaxis |
|
|
221 | (4) |
|
15 Adverse Reactions to Antimicrobial Agents |
|
|
225 | (8) |
|
|
233 | (6) |
Appendix: Nomogram for Determining Body Surface Area |
|
239 | (2) |
References |
|
241 | (22) |
Index |
|
263 | |